AB0180 CLINICAL AND ULTRASOUND-BASED COMPOSITE DISEASE ACTIVITY INDICES AND RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS
Authors: I. Gessl, T. Deimel, P. Studenic, G. Tamborrini, P. Zufferey, D. Aletaha, B. Moeller, P. Mandl
Journal: Annals of the Rheumatic Diseases (2022)

Background Musculoskeletal ultrasound (US) has been reported to predict radiographic progression in rheumatoid arthritis (RA). Objectives To test the predictive value of composite disease activity indices (DAI) based on solely clinical as well as clinical and US (USDAI) information to predict radiographic progression in RA. Methods Data from the Swiss Clinical Quality Management (SCQM) database were extracted from patients with RA; USDAIs were created based on previous publications (1) (Table 1). In summary, the disease activity score in 28 joints (DAS28) and the simplified disease activity index (SDAI) were modified by supplementing or replacing the clinical swollen JC with joints showing signs of power Doppler (PD) and/or grey scale (GS) synovitis. Series with two standard x-rays of the hands (difference ≥ 183 days) and ≥1 visit with clinical and US data in between were analyzed. Progression was defined as an increase of ≥6.27 points of the Ratingen-Rau x-ray score. Receiver operating curve (ROC) analyses were used to assess predictive ability of every DAI for radiographic progression. As a subanalysis, ROCs using the median DAIs of series with ≥2 DAIs between two x-rays were run. Clinical DAS28/SDAIs were compared to their respective USDAI counterpart with the highest area under the curves (AUC). Table 1. Area under the curves (AUC) of receiver operating characteristic curves for the predictive value of the composite disease activity indices for radiographic progression. DAI disease activity index ; DAS28, disease activity score for 28 joints; GS, grey scale; PD, power Doppler; SDAI, simplified disease activity index; SJC: swollen joint count; + positive Disease activity indexes All series Series with ≥ 2 DAIs 95% CI 95% CI AUC Lower Upper AUC Lower Upper DAS28 .58 .52 .58 .62 .45 .78 DAS28 _ GS SJC replaced by GS+ joints .56 .49 .56 .62 .44 .80 DAS28 _ PD SJC replaced by PD+ joints .60 .53 .60 .63 .46 .81 DAS28_GSPD SJC replaced by GS AND PD+ joints .57 .50 .57 .62 .44 .80 DAS28 _ plus _ GS SJC supplemented by GS+ joints .57 .50 .57 .62 .44 .8ß DAS28_plus_PD SJC supplemented by PD+ joints .59 .52 .59 .61 .43 .79 DAS28 _ plus _ GSPD SJC supplemented by GS AND PD+ joints .57 .50 .57 .62 .44 .79 SDAI .57 .50 .57 .48 .26 .70 SDAI_GS SJC replaced by GS+ joints .53 .46 .53 .47 .23 .71 SDAI _ PD SJC replaced by PD+ joints .58 .52 .58 .51 .27 .75 SDAI _ GSPD SJC replaced by GS AND PD+ joints .53 .46 .53 .47 .23 .71 SDAI _ plus _ GS SJC supplemented by GS+ joints .54 .47 .54 .47 .23 .70 SDAI _ plus _ PD SJC supplemented by PD+ joints .58 .51 .58 .48 .25 .72 SDAI _ plus _ GSPD SJC supplemented by GS AND PD+ joints .54 .47 .54 .46 .23 .70 Results We included 649 series in 475 patients. Progression was observed in 84/649 (12.9%) series. Mean difference between the x-rays was 27.6±18.0 months. Mean age was 56.3±12.7 years, 474/649 (73%) series were from female patients. There was no significant difference between the AUC of the ROC of SDAI vs. SDAI_PD (p=0.19) nor between DAS28 vs. DAS28_PD: (p=0.17) (Figure 1A, Table 1). Similarly, when analyzing only series with ≥2 DAIs (143 series) we observed no difference between the AUC of the ROC of SDAI vs. SDAI-PD (p=0.28) nor between that of DAS28 vs. DAS28_PD (p=0.23) (Figure 1B, Table 1). Figure 1. Receiver operating characteristic (ROC) curve of clinical and ultrasound-based composite disease activity indices (A) overall and (B) for the subgroup with series with ≥ disease activity indices. DAS, disease activity score; GS, grey scale; PD, power Doppler; SDAI, simplified disease activity index; Conclusion The predictability of radiographic progression by disease activity measures was generally limited. The composite USDAIs containing sonographic JC were not superior for predicting radiographic progression compared to their clinical counterparts although there was a trend for higher predictive value for indices containing PD. References [1]Mandl P, Balint P, Brault Y et al. Arthritis Care Res 2013;65:879-87. Disclosure of Interests Irina Gessl: None declared, Thomas Deimel: None declared, Paul Studenic: None declared, Giorgio Tamborrini: None declared, Pascal Zufferey: None declared, Daniel Aletaha Speakers bureau: Abbvie, Amgen, Lilly, Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Grant/research support from: Abbvie, Amgen, Lilly, Novartis, Roche, SoBi, Sanofi, Burkhard Moeller: None declared, Peter Mandl Speakers bureau: from AbbVie, Janssen and Novartis, Grant/research support from: from AbbVie, BMS, Novartis, Janssen, MSD and UCB